International Speakers

Below is the list of international invited speakers for NDLR 2020.
To view national speakers. click here.

Ann Mullally (USA)

Dana Farber/Harvard Cancer Center

Dr. Ann Mullally is an Associate Professor of Medicine at Harvard Medical School and a physician-scientist at Brigham and Women’s Hospital (BWH). She holds a weekly clinic for patients with myeloproliferative neoplasms (MPN) at Dana-Farber Cancer Institute (DFCI) and runs a research laboratory focused on myeloid malignancies, primarily MPN. Her clinical interests include early intervention strategies to target disease-propagating MPN stem cells and the development of immunological approaches to target mutant calreticulin (CALR) in MPN. Her laboratory studies the genetics, biology and therapy of MPN using primary patient samples, mouse models and multiple in vitro model systems. Dr. Mullally’s laboratory research interests include the biology of mutant CALR and JAK2V617F in MPN, the biology of myelofibrosis, MPN stem cells and the development of novel therapeutic strategies to preferentially target them. The overarching goal of her research is to advance the understanding of the biology of MPN and to translate this into improved treatment options for patients dealing with these diseases.

Click here for more information on the Mullally Laboratory.

Marion Subklewe (Germany)

Gene Center Munich  

Head of the Laboratory for Translational Cancer Immunology
Gene Center Munich, LMU

Since 2014 Professor for Internal Medicine with focus on Cellular Immunotherapy
Medical Department III, Hematology / Oncology, Klinikum – University of Munich

Click here for more information on the Subklewe Laboratory. 

Ravindra Majeti (USA)

Stanford University School of Medicine

Ravi Majeti MD, PhD is Professor of Medicine, Chief of the Division of Hematology, and Member of the Institute for Stem Cell Biology and Regenerative Medicine at the Stanford University School of Medicine. He was an undergraduate at Harvard, earned his MD and PhD from UCSF, and trained in Internal Medicine at Brigham and Women’s Hospital in Boston. Dr. Majeti completed his Hematology Fellowship at Stanford, and is a board-certified hematologist. While at Stanford, he completed post-doctoral training in the laboratory of Irving Weissman, where he investigated acute myeloid leukemia (AML) stem cells and therapeutic targeting with anti-CD47 antibodies.. Dr. Majeti directs an active NIH-funded laboratory that focuses on the molecular characterization and therapeutic targeting of leukemia stem cells in human hematologic disorders, particularly AML, and has published >90 peer-reviewed articles. He is a recipient of the Burroughs Wellcome Career Award for Medical Scientists, the New York Stem Cell Foundation Robertson Investigator Award, and the Leukemia and Lymphoma Society Scholar Award. Dr. Majeti is currently a member of the Committee on Scientific Affairs for the American Society of Hematology (ASH) and serves of the editorial boards of Blood and eLife.

Click here for more information on Majeti Laboratory

Elli Papaemmanuil (USA)

Memorial Sloan Kettering Cancer Center

Dr. Papaemmanuil got her BSc and MSci in Human Molecular Genetics with Honors at the University of Glasgow and her PhD in Human population genetics at the Institute of Cancer Research in London. She performed her postdoctoral studies at the Wellcome Trust Sanger Center and joined the University of Cambridge as faculty, prior to moving to the Memorial Sloan Kettering Cancer Center. 

Dr. Papaemmanuil has employed genome profiling methodologies to study role of acquired mutations in cancer development and how these determine clinical phenotype and response to therapy. Her main research motivation is to develop research that helps translate recent cancer genome discoveries into clinical practice. Her current research spans, bioinformatic and algorithmic platform development, biomarker discovery and validation and experimental models of disease biology. 

Click here for more information

Christian Steidl (Canada)

BC Cancer Research Center, Vancouver

Dr Steidl is the Research Director of the Centre for Lymphoid Cancer, Associate Vice President Research at BC Cancer and Associate Professor in the Department of Pathology and Laboratory Medicine at the University of British Columbia. He has expertise in clinical malignant hematology, molecular pathology, genomics and lymphoma biology. Dr Steidl’s translational research group focuses on the pathogenesis of B cell lymphomas, tumor microenvironment biology and applied genomics. He is most known for his discovery and characterization of novel gene mutations in Non-Hodgkin lymphomas and microenvironment-related biomarkers in Hodgkin lymphoma. Dr Steidl is a member of the Scientific Advisory Board of the Lymphoma Research Foundation, past chair of the American Society of Hematology Scientific Committee on Lymphoid Neoplasia and Member of the Leukemia and Lymphoma Society of Canada Medical and Scientific Advisory Committee. He was inducted as a member of the Royal Society of Canada, College for New Scholars, Artists and Scientists in 2017, and won an Allen Distinguished Investigator award in 2018.

Click here for more information